A RANDOMIZED CONTROLLED TRIAL OF CAMOSTAT IN OUTPATIENTS WITH COVID-19
Camostat, an oral protease inhibitor, blocks entry and replication of SARS-CoV-1 and SARS-CoV-2 in vitro. It is approved for therapy of recurrent pancreatitis in several countries. Camostat has an excellent safety profile and repurposing for COVID-19 treatment was proposed. We conducted a phase 2 randomized, placebo-controlled trial of camostat in adult outpatients with confirmed COVID-19…